Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment ...
Once-daily roflumilast demonstrated favorable safety and tolerability over 52 to 64 weeks of treatment At 52 to 64 weeks of treatment, 44% of subjects had attained an IGA of clear or almost clear Preliminary data further support the potential of …